Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: This systematic review aims to evaluate loteprednol etabonate's efficacy and safety in reducing post-cataract pain and inflammation.
Methods: A literature search was conducted to identify randomized controlled trials comparing loteprednol etabonate and placebo for post-cataract pain and inflammation. The primary outcome was the proportion of patients with complete resolution of anterior chamber inflammation (ACI) and grade zero pain. The quality of the studies was assessed using the RoB 2 tool, and a meta-analysis was performed using RevMan 5 software.
Results: This systematic review identified eight clinical trials (n=3,332 patients) fulfilling research criteria. Meta-analysis results showed that loteprednol etabonate significantly improved ACI resolution compared with placebo at 8, 15, and 18 days postoperatively (RR=2.25, 2.11, and 2.06, respectively, with a P value <0.00001). Loteprednol etabonate also increased the likelihood of achieving no pain (RR=1.54, 1.66, 1.70, and 1.92, respectively, with a P value <0.00001) and reduced the need for rescue therapy (RR=0.47, P<0.00001) while maintaining no change in IOP after 3, 15, and 18 days.
Conclusion: Loteprednol etabonate demonstrates significant efficacy in alleviating pain and inflammation post-cataract surgery, with notable advantages in safety, including minimal impact on intraocular pressure and reduced adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICL.0000000000001210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Loteprednol Etabonate in Managing Pain and Inflammation After Cataract Surgery: A Systematic Review and Meta-analysis.
Eye Contact Lens
August 2025
Faculty of Medicine (A.M.E., M.A.A., M.M.S., A.A.A.E.), Mansoura University, Mansoura, Egypt; Department of Ophthalmology (N.A.A., W.A.A.), College of Medicine, King Khalid University, Abha, Saudi Arabia; and Consultant Ophthalmology King Khalid University Medical City (S.M.A.S.), Abha, Saudi Arabia
Objectives: This systematic review aims to evaluate loteprednol etabonate's efficacy and safety in reducing post-cataract pain and inflammation.
Methods: A literature search was conducted to identify randomized controlled trials comparing loteprednol etabonate and placebo for post-cataract pain and inflammation. The primary outcome was the proportion of patients with complete resolution of anterior chamber inflammation (ACI) and grade zero pain.
Which topical ophthalmic drugs work best for Keratoconjunctivitis Sicca? A systematic review and meta-analysis.
Naunyn Schmiedebergs Arch Pharmacol
July 2025
Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan.
Background: Dry Eye Disease (DED) is a chronic and multifactorial condition that significantly impacts patient quality of life. Topical ophthalmic drugs (TODs) have emerged as key treatments for DED, offering the potential to address the underlying pathology rather than merely alleviating symptoms. This review aims to assess the efficacy of various TODs in managing the symptoms of DED.
View Article and Find Full Text PDFPCR-Based Evaluation of Viral Load Reduction in Adenoviral Conjunctivitis: A Comparative Study of Ganciclovir and Povidone-Iodine.
Ocul Immunol Inflamm
July 2025
Department of Ophthalmology and Visual Sciences, West Virginia University Eye Institute, Morgantown, West Virginia, USA.
Purpose: To evaluate the efficacy of topical ganciclovir (GCV), povidone-iodine (PVP-I), and their combination with loteprednol etabonate (LE) in reducing viral load and improving clinical outcomes in adenoviral conjunctivitis.
Methods: This single-centered, controlled study enrolled patients diagnosed with adenoviral conjunctivitis, confirmed by the Rapid Pathogen Screening Adeno-Detector Plus test. Participants were assigned to five treatment groups: artificial tears (AT) as the control group, and the treatment groups included PVP-I, GCV, PVP-I/LE, and GCV/LE.
Mucoadhesive micellar eyedrops for the treatment of ocular inflammation.
Acta Biomater
July 2025
Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA, 90095, United States; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, United States. Electronic address:
Efficient ocular drug delivery remains a significant challenge in treating eye inflammation due to physiological barriers such as the tear film and frequent blinking, which lead to rapid drug clearance. Commercial eyedrops, like Oceanside® (0.5 % loteprednol etabonate (LE) ophthalmic suspension), suffer from low ocular bioavailability and require frequent dosing to maintain therapeutic levels.
View Article and Find Full Text PDFChildhood-onset ocular mucous membrane pemphigoid presenting with peripheral ulcerative keratitis: a case report and review of the literature.
J Ophthalmic Inflamm Infect
May 2025
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico.
Purpose: The purpose of this study was to describe the case of a pediatric patient diagnosed with mucous membrane pemphigoid (MMP) with exclusive ocular involvement presenting at diagnosis with peripheral ulcerative keratitis and provide a review of the literature.
Methods: A 12-year-old girl presented with cicatricial conjunctivitis and peripheral ulcerative keratitis (PUK). A conjunctival biopsy and direct immunofluorescence revealed linear deposits of IgG, IgM, and C3 at the basement membrane zone, confirming a diagnosis of ocular MMP.